{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:28Z","timestamp":1793908648867,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and development","doi-asserted-by":"crossref","award":["JP19fk0210031"],"award-info":[{"award-number":["JP19fk0210031"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and development","doi-asserted-by":"crossref","award":["JP19fk0210031"],"award-info":[{"award-number":["JP19fk0210031"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and development","doi-asserted-by":"crossref","award":["JP19fk0210031"],"award-info":[{"award-number":["JP19fk0210031"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and development","doi-asserted-by":"crossref","award":["JP19fk0210031"],"award-info":[{"award-number":["JP19fk0210031"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H03532"],"award-info":[{"award-number":["18H03532"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K20870"],"award-info":[{"award-number":["21K20870"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K16026"],"award-info":[{"award-number":["18K16026"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H06222"],"award-info":[{"award-number":["18H06222"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K11766"],"award-info":[{"award-number":["19K11766"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K11020"],"award-info":[{"award-number":["18K11020"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08383"],"award-info":[{"award-number":["20K08383"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although patients with nonalcoholic fatty liver disease have been reported to have cardiac dysfunction, and appropriate model has not been reported. We established a novel mouse model of diet-induced steatohepatitis-related cardiomyopathy and evaluated the effect of pemafibrate. C57Bl\/6 male mice were fed a (1) chow diet (C), (2) high-fat, high-cholesterol, high-sucrose, bile acid diet (NASH diet; N), or (3) N with pemafibrate 0.1\u00a0mg\/kg (NP) for 8\u00a0weeks. In the liver, macrophage infiltration and fibrosis in the liver was observed in the N group compared to the C group, suggesting steatohepatitis. Free cholesterol accumulated, and cholesterol crystals were observed. In the heart, free cholesterol similarly accumulated and concentric hypertrophy was observed. Ultrahigh magnetic field magnetic resonance imaging revealed that the left ventricular (LV) ejection fraction (EF) was attenuated and LV strain was focally impaired. RNA sequencing demonstrated that the NOD-like receptor and PI3 kinase-Akt pathways were enhanced. mRNA and protein expression of inflammasome-related genes, such as Caspase-1, NLRP3, and IL-1\u03b2, were upregulated in both the liver and heart. In the NP compared to the N group, steatohepatitis, hepatic steatosis, and cardiac dysfunction were suppressed. Sequential administration of pemafibrate after the development of steatohepatitis-related cardiomyopathy recovered hepatic fibrosis and cardiac dysfunction.<\/jats:p>","DOI":"10.1038\/s41598-022-06542-8","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T11:02:51Z","timestamp":1645527771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy"],"prefix":"10.1038","volume":"12","author":[{"given":"Kotaro","family":"Kanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Asaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Higo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Okuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Ohama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiji","family":"Saibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"6542_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.) 64, 73\u201384. https:\/\/doi.org\/10.1002\/hep.28431 (2016).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"6542_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389-397 e310. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043 (2015).","journal-title":"Gastroenterology"},{"key":"6542_CR3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep4.1155","volume":"2","author":"YY Zhou","year":"2018","unstructured":"Zhou, Y. Y. et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol. Commun. 2, 376\u2013392. https:\/\/doi.org\/10.1002\/hep4.1155 (2018).","journal-title":"Hepatol. Commun."},{"key":"6542_CR4","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon, T. G., Roelstraete, B., Khalili, H., Hagstrom, H. & Ludvigsson, J. F. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70, 1375\u20131382. https:\/\/doi.org\/10.1136\/gutjnl-2020-322786 (2021).","journal-title":"Gut"},{"key":"6542_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00535-013-0911-1","volume":"49","author":"T Nakahara","year":"2014","unstructured":"Nakahara, T. et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J. Gastroenterol. 49, 1477\u20131484. https:\/\/doi.org\/10.1007\/s00535-013-0911-1 (2014).","journal-title":"J. Gastroenterol."},{"key":"6542_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"6542_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jhep.2017.11.023","volume":"68","author":"YH Lee","year":"2018","unstructured":"Lee, Y. H. et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J. Hepatol. 68, 764\u2013772. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.023 (2018).","journal-title":"J. Hepatol."},{"key":"6542_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.amjcard.2018.10.027","volume":"123","author":"JM Canada","year":"2019","unstructured":"Canada, J. M. et al. Relation of hepatic fibrosis in nonalcoholic fatty liver disease to left ventricular diastolic function and exercise tolerance. Am. J. Cardiol 123, 466\u2013473. https:\/\/doi.org\/10.1016\/j.amjcard.2018.10.027 (2019).","journal-title":"Am. J. Cardiol"},{"key":"6542_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/s0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura, H. et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. The Lancet 368, 1155\u20131163. https:\/\/doi.org\/10.1016\/s0140-6736(06)69472-5 (2006).","journal-title":"The Lancet"},{"key":"6542_CR10","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1161\/ATVBAHA.119.312336","volume":"39","author":"K Suzuki","year":"2019","unstructured":"Suzuki, K. et al. Elevated serum Non-HDL (high-density lipoprotein) cholesterol and triglyceride levels as residual risks for myocardial infarction recurrence under statin treatment. Arterioscler. Thromb. Vasc. Biol. 39, 934\u2013944. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312336 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"6542_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"A. S.","year":"2010","unstructured":"Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563\u20131574. https:\/\/doi.org\/10.1056\/NEJMoa1001282 (2010).","journal-title":"N. Engl. J. Med."},{"key":"6542_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai, H. et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 261, 144\u2013152. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.032 (2017).","journal-title":"Atherosclerosis"},{"key":"6542_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart, J. C. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc. Diabetol. 16, 124. https:\/\/doi.org\/10.1186\/s12933-017-0602-y (2017).","journal-title":"Cardiovasc. Diabetol."},{"key":"6542_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-019-0845-x","volume":"18","author":"S Ida","year":"2019","unstructured":"Ida, S., Kaneko, R. & Murata, K. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc. Diabetol. 18, 38. https:\/\/doi.org\/10.1186\/s12933-019-0845-x (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"6542_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","volume":"18","author":"JC Fruchart","year":"2019","unstructured":"Fruchart, J. C. et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) paradigm: conceptual framework and therapeutic potential\u202f: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc. Diabetol. 18, 71. https:\/\/doi.org\/10.1186\/s12933-019-0864-7 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"6542_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11883-020-00897-x","volume":"23","author":"JC Fruchart","year":"2021","unstructured":"Fruchart, J. C., Hermans, M. P., Fruchart-Najib, J. & Kodama, T. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha) in the metabolic syndrome: is pemafibrate light at the end of the tunnel?. Curr. Atheroscler. Rep. 23, 3. https:\/\/doi.org\/10.1007\/s11883-020-00897-x (2021).","journal-title":"Curr. Atheroscler. Rep."},{"key":"6542_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan, A. D. et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am. Heart J. 206, 80\u201393. https:\/\/doi.org\/10.1016\/j.ahj.2018.09.011 (2018).","journal-title":"Am. Heart J."},{"key":"6542_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/ijms19072148","volume":"19","author":"M Araki","year":"2018","unstructured":"Araki, M. et al. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist pemafibrate protects against diet-induced obesity in mice. Int. J. Mol. Sci. 19, 102. https:\/\/doi.org\/10.3390\/ijms19072148 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"6542_CR19","doi-asserted-by":"publisher","first-page":"42477","DOI":"10.1038\/srep42477","volume":"7","author":"Y Honda","year":"2017","unstructured":"Honda, Y. et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci. Rep. 7, 42477. https:\/\/doi.org\/10.1038\/srep42477 (2017).","journal-title":"Sci. Rep."},{"key":"6542_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12933-020-01132-2","volume":"19","author":"M Yoshida","year":"2020","unstructured":"Yoshida, M. et al. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl\/salt-sensitive rats fed a high-salt and high-fat diet. Cardiovasc. Diabetol. 19, 149. https:\/\/doi.org\/10.1186\/s12933-020-01132-2 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"6542_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5551\/jat.9.87","volume":"9","author":"S Maruyama","year":"2002","unstructured":"Maruyama, S. et al. Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats. J. Atheroscler. Thromb. 9, 87\u201392. https:\/\/doi.org\/10.5551\/jat.9.87 (2002).","journal-title":"J. Atheroscler. Thromb."},{"key":"6542_CR22","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.1038\/s41598-018-25699-9","volume":"8","author":"BM Kim","year":"2018","unstructured":"Kim, B. M., Abdelfattah, A. M., Vasan, R., Fuchs, B. C. & Choi, M. Y. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis. Sci. Rep. 8, 7499. https:\/\/doi.org\/10.1038\/s41598-018-25699-9 (2018).","journal-title":"Sci. Rep."},{"key":"6542_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","volume":"133","author":"K Takei","year":"2017","unstructured":"Takei, K. et al. Effects of K-877, a novel selective PPARalpha modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. J. Pharmacol. Sci. 133, 214\u2013222. https:\/\/doi.org\/10.1016\/j.jphs.2017.02.003 (2017).","journal-title":"J. Pharmacol. Sci."},{"key":"6542_CR24","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1128\/mcb.22.8.2799-2809.2002","volume":"22","author":"T Shioi","year":"2002","unstructured":"Shioi, T. et al. Akt\/protein kinase B promotes organ growth in transgenic mice. Mol. Cell Biol. 22, 2799\u20132809. https:\/\/doi.org\/10.1128\/mcb.22.8.2799-2809.2002 (2002).","journal-title":"Mol. Cell Biol."},{"key":"6542_CR25","doi-asserted-by":"publisher","first-page":"12333","DOI":"10.1073\/pnas.172376399","volume":"99","author":"G Condorelli","year":"2002","unstructured":"Condorelli, G. et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. U S A 99, 12333\u201312338. https:\/\/doi.org\/10.1073\/pnas.172376399 (2002).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"6542_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14044","volume":"39","author":"A Mantovani","year":"2019","unstructured":"Mantovani, A. et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 39, 758\u2013769. https:\/\/doi.org\/10.1111\/liv.14044 (2019).","journal-title":"Liver Int."},{"key":"6542_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.5551\/jat.40956","volume":"25","author":"S Watanabe","year":"2018","unstructured":"Watanabe, S. et al. A high-fat and high-cholesterol diet induces cardiac fibrosis, vascular endothelial, and left ventricular diastolic dysfunction in SHRSP5\/Dmcr rats. J. Atheroscler. Thromb. 25, 439\u2013453. https:\/\/doi.org\/10.5551\/jat.40956 (2018).","journal-title":"J. Atheroscler. Thromb."},{"key":"6542_CR28","doi-asserted-by":"publisher","first-page":"154707","DOI":"10.1016\/j.metabol.2021.154707","volume":"117","author":"F Briand","year":"2021","unstructured":"Briand, F. et al. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. Metabol. Clin. Exp. 117, 154707. https:\/\/doi.org\/10.1016\/j.metabol.2021.154707 (2021).","journal-title":"Metabol. Clin. Exp."},{"key":"6542_CR29","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/hep.21874","volume":"46","author":"N Matsuzawa","year":"2007","unstructured":"Matsuzawa, N. et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology (Baltimore, Md.) 46, 1392\u20131403. https:\/\/doi.org\/10.1002\/hep.21874 (2007).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"6542_CR30","doi-asserted-by":"publisher","first-page":"614692","DOI":"10.3389\/fendo.2020.614692","volume":"11","author":"J Chang","year":"2020","unstructured":"Chang, J. et al. Dietary oxysterol, 7-ketocholesterol accelerates hepatic lipid accumulation and macrophage infiltration in obese mice. Front. Endocrinol. (Lausanne) 11, 614692. https:\/\/doi.org\/10.3389\/fendo.2020.614692 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"6542_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/CIRCULATIONAHA.110.982777","volume":"123","author":"M Kawaguchi","year":"2011","unstructured":"Kawaguchi, M. et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia\/reperfusion injury. Circulation 123, 594\u2013604. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.982777 (2011).","journal-title":"Circulation"},{"key":"6542_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/eurheartj\/ehx261","volume":"39","author":"H Xiao","year":"2018","unstructured":"Xiao, H. et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon beta-adrenergic insult. Eur. Heart J. 39, 60\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehx261 (2018).","journal-title":"Eur. Heart J."},{"key":"6542_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/liv.12478","volume":"35","author":"M Sato","year":"2015","unstructured":"Sato, M. et al. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int. Off. J. Int. Assoc. Study Liver 35, 925\u2013935. https:\/\/doi.org\/10.1111\/liv.12478 (2015).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"6542_CR34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RCR Meex","year":"2017","unstructured":"Meex, R. C. R. & Watt, M. J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 13, 509\u2013520. https:\/\/doi.org\/10.1038\/nrendo.2017.56 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"6542_CR35","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2020.10.030","volume":"74","author":"O Kucukoglu","year":"2021","unstructured":"Kucukoglu, O., Sowa, J. P., Mazzolini, G. D., Syn, W. K. & Canbay, A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J. Hepatol. 74, 442\u2013457. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.030 (2021).","journal-title":"J. Hepatol."},{"key":"6542_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.gastro.2011.09.049","volume":"142","author":"T Teratani","year":"2012","unstructured":"Teratani, T. et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142, 152-164 e110. https:\/\/doi.org\/10.1053\/j.gastro.2011.09.049 (2012).","journal-title":"Gastroenterology"},{"key":"6542_CR37","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehr127","volume":"33","author":"F Montecucco","year":"2012","unstructured":"Montecucco, F. et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur. Heart J. 33, 1964\u20131974. https:\/\/doi.org\/10.1093\/eurheartj\/ehr127 (2012).","journal-title":"Eur. Heart J."},{"key":"6542_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1873-9598(08)70018-8","volume":"1","author":"SKM Takashima","year":"2007","unstructured":"Takashima, S. K. M. HB-EGF, transactivation, and cardiac hypertrophy. Int. J. Gerontol. 1, 2\u20139 (2007).","journal-title":"Int. J. Gerontol."},{"key":"6542_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jmri.20473","volume":"23","author":"WY Tseng","year":"2006","unstructured":"Tseng, W. Y., Dou, J., Reese, T. G. & Wedeen, V. J. Imaging myocardial fiber disarray and intramural strain hypokinesis in hypertrophic cardiomyopathy with MRI. J. Magn. Reson. Imaging 23, 1\u20138. https:\/\/doi.org\/10.1002\/jmri.20473 (2006).","journal-title":"J. Magn. Reson. Imaging"},{"key":"6542_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jcmg.2017.04.006","volume":"11","author":"S Nakamori","year":"2018","unstructured":"Nakamori, S. et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc. Imaging 11, 48\u201359. https:\/\/doi.org\/10.1016\/j.jcmg.2017.04.006 (2018).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"6542_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16596","author":"A Nakajima","year":"2021","unstructured":"Nakajima, A. et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. https:\/\/doi.org\/10.1111\/apt.16596 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"6542_CR42","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.5551\/jat.ER39693","volume":"25","author":"M Sairyo","year":"2018","unstructured":"Sairyo, M. et al. A novel selective PPARalpha modulator (SPPARMalpha), K-877 (Pemafibrate), attenuates postprandial hypertriglyceridemia in mice. J. Atheroscler. Thromb. 25, 1086. https:\/\/doi.org\/10.5551\/jat.ER39693 (2018).","journal-title":"J. Atheroscler. Thromb."},{"key":"6542_CR43","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","volume":"274","author":"P Delerive","year":"1999","unstructured":"Delerive, P. et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274, 32048\u201332054. https:\/\/doi.org\/10.1074\/jbc.274.45.32048 (1999).","journal-title":"J. Biol. Chem."},{"key":"6542_CR44","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore Md.) 41, 1313\u20131321. https:\/\/doi.org\/10.1002\/hep.20701 (2005).","journal-title":"Hepatology (Baltimore Md.)"},{"key":"6542_CR45","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36. https:\/\/doi.org\/10.1186\/gb-2013-14-4-r36 (2013).","journal-title":"Genome Biol."},{"key":"6542_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359. https:\/\/doi.org\/10.1038\/nmeth.1923 (2012).","journal-title":"Nat. Methods"},{"key":"6542_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab007","author":"JK Bonfield","year":"2021","unstructured":"Bonfield, J. K. et al. HTSlib: C library for reading\/writing high-throughput sequencing data. Gigascience https:\/\/doi.org\/10.1093\/gigascience\/giab007 (2021).","journal-title":"Gigascience"},{"key":"6542_CR48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511\u2013515. https:\/\/doi.org\/10.1038\/nbt.1621 (2010).","journal-title":"Nat. Biotechnol."},{"key":"6542_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12194-018-0490-1","volume":"12","author":"S Saito","year":"2019","unstructured":"Saito, S., Takahashi, Y., Ohki, A., Shintani, Y. & Higuchi, T. Early detection of elevated lactate levels in a mitochondrial disease model using chemical exchange saturation transfer (CEST) and magnetic resonance spectroscopy (MRS) at 7T-MRI. Radiol. Phys. Technol. 12, 46\u201354. https:\/\/doi.org\/10.1007\/s12194-018-0490-1 (2019).","journal-title":"Radiol. Phys. Technol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06542-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:14:13Z","timestamp":1669331653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06542-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6542"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06542-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was financially supported by a research grant from Kowa Company, Ltd. M.K., S.Y., and Y.S. report a lecture fee from Kowa company, Ltd., and S.Y. received consultant fees from Skylight Biotech, Inc.; however, they are not employees of these companies. K.K., J.C., A.S., H.I., T.O., K.T., M.A., Y.Z., S.I., S.S., T.H., D.O., T.O., M.N., Y.K., M.O., and T.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2996"}}